Pharm Sci Seminar – Robert Kerns, PhD
Abstract coming soon
Stay up-to-date with the latest events, including faculty presentations, career events for students and alumni, and so much more.
Abstract coming soon
Antibiotic resistance is a serious public health crisis. Antibacterial regulatory guidelines have been recently updated to allow for more streamlined development of narrow-spectrum, precision therapies to treat highly problematic, multidrug-resistant bacterial infections
DNA Topoisomerase IIα (TOP2α; 170 kDa) is a prominent target for anticancer drugs whose clinical efficacy is often compromised due to acquired chemoresistance.
We use the Drosophila prothoracic gland (PG) as a model to study tissues with high and dynamic demands in iron and heme.
In the solid state, small molecules such as active pharmaceutical ingredient (API) molecules tend to pack in well defined arrangements leading to different crystalline polymorphs
ncreasingly we seek smarter ways to deliver therapies in a targeted way. Nanoscience can play an important role in this endeavor
Bile acids (BA) are biological surfactants synthesized in the liver and secreted to the duodenum via the gall bladder to help digest dietary fats.
Molecular docking screens large compound libraries for molecules that complement a binding site, but do not resemble known ligands
Methyl-lysine (Kme) recognition domains play a central role in chromatin regulation during cellular differentiation, development, and gene transcription with more than 200 known Kme “reader” domains
This seminar will share our work on the development & clinical translation of nanotherapeutics in cancer chemoradiotherapy treatment, on recent work on applying nanotechnology to improve cancer immunotherapy, and the application of tissue engineering for cancer model development